Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have received an average recommendation of “Hold” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $12.6667.

A number of brokerages have issued reports on VRCA. Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Lake Street Capital started coverage on shares of Verrica Pharmaceuticals in a research note on Thursday, August 27th. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Finally, HC Wainwright started coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price objective for the company.

Verrica Pharmaceuticals Trading Down 4.3%

NASDAQ:VRCA opened at $4.45 on Monday. The stock has a market cap of $76.45 million, a PE ratio of -2.66 and a beta of 1.49. Verrica Pharmaceuticals has a fifty-two week low of $3.28 and a fifty-two week high of $9.82. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.45 and a quick ratio of 1.33. The stock’s 50-day moving average is $5.18 and its two-hundred day moving average is $5.73.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Verrica Pharmaceuticals stock. Renaissance Technologies LLC grew its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 22.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,360 shares of the company’s stock after buying an additional 5,960 shares during the period. Renaissance Technologies LLC owned approximately 0.19% of Verrica Pharmaceuticals worth $171,000 as of its most recent SEC filing. Institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company’s work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options.

Verrica’s lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older.